Godsey & Gibb Inc’s ImmunityBio IBRX Stock Holding History

Godsey & Gibb Inc’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-46,100	Closed	-$91.3K	–	415
2025 Q4	$91.3K	Sell	46,100 -8,000	-15%	-$18.1K	0.01%	146
2025 Q3	$133K	Buy	+54,100	New	+$139K	0.01%	128

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Godsey & Gibb Inc's IBRX Position: Q1 2026 in Review

Godsey & Gibb Inc sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 46,100 shares — an estimated $91.3K sold.

Godsey & Gibb Inc first reported a position in IBRX in Q3 2025 and held it in 2 quarters. The position peaked at $133K in Q3 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Godsey & Gibb Inc reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Godsey & Gibb Inc sold 46,100 ImmunityBio shares in Q1 2026, an estimated $91.3K.
Godsey & Gibb Inc first reported a position in ImmunityBio in Q3 2025 and held it in 2 quarters.
Godsey & Gibb Inc's ImmunityBio position peaked at $133K in Q3 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Godsey & Gibb Inc's 13F filing for Q1 2026, filed 20 Apr 2026.